Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) Shares Outstanding (Diluted Average) (2017 - 2021)

Pediatrix Medical (MD) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $85.5 million as the latest value for Q1 2021.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 3.25% to $85.5 million in Q1 2021 year-over-year; TTM through Mar 2021 was $85.5 million, a 3.25% increase, with the full-year FY2020 number at $85.1 million, up 2.15% from a year prior.
  • Shares Outstanding (Diluted Average) was $85.5 million for Q1 2021 at Pediatrix Medical, roughly flat from $85.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $93.5 million in Q2 2018 to a low of $82.8 million in Q1 2020.
  • A 5-year average of $87.2 million and a median of $85.3 million in 2020 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): fell 10.52% in 2019, then rose 3.25% in 2021.
  • Pediatrix Medical's Shares Outstanding (Diluted Average) stood at $93.0 million in 2017, then fell by 1.45% to $91.6 million in 2018, then decreased by 9.08% to $83.3 million in 2019, then increased by 2.15% to $85.1 million in 2020, then grew by 0.48% to $85.5 million in 2021.
  • Per Business Quant, the three most recent readings for MD's Shares Outstanding (Diluted Average) are $85.5 million (Q1 2021), $85.1 million (Q4 2020), and $83.9 million (Q3 2020).